Safety and Efficacy of Generic Sofosbuvir and Ribavirin for Treatment-naive Genotype 2 Chronic Hepatitis C
Status:
Completed
Trial end date:
2017-03-30
Target enrollment:
Participant gender:
Summary
This study aimed to evaluate the safety and efficacy of generic sofosbuvir, an
investigational anti-hepatitis C virus (HCV) drug, combined with weight-adjusted ribavirin
for treatment-naive Chinese adults chronically infected with genotype 2 HCV, the second most
prevalent genotype in China. One hundred and thirty-two (132) subjects, including one hundred
and twenty (120) non-cirrhotics and twelve (12) compensatory cirrhotics, were medicated with
sofosbuvir 400 mg daily combined with weight-adjusted ribavirin 1000-1200 mg daily. The
treatment course lasted 12 successive weeks and thereafter all the study participants entered
into a 12-week treatment-free follow-up period.